Reactive oxygen species levels differentiate CD34+ human progenitors based on CD38 expression.
Christine VignonSébastien LachotAmélie FoucaultNoémie RavaletEmmanuel GyanFrédéric PicouBeatrice HeraultLouis-Romée Le NailMarie Christine BeneOlivier HeraultPublished in: Cytometry. Part B, Clinical cytometry (2020)
Low reactive oxygen species (ROS) levels are well-established characteristics of mouse hematopoietic stem cells (HSCs). However, little is known about these levels in human HSCs. This study aimed at quantifying ROS levels in human CD34+ CD38low and CD34+ CD38high human progenitors from bone marrow, cord blood and cells mobilized for autologous HSC transplantation. A specifically devised multiparameter flow cytometry method was used to quantify ROS levels (H2 DCFDA staining) in sub-populations of primary cells. Results were confirmed by assessing gene expression level of the ROS scavenger GPX3, a key determinant of HSC self-renewal, in sorted CD34+ CD38low and CD34+ CD38high cells. CD34+ CD38low cells from bone marrow and cord blood displayed significantly lower levels of ROS than CD34+ CD38high cells and other leukocytes. Moreover, the correlation between ROS and GPX3 expression was verified in sorted CD34+ CD38low and CD34+ CD38high cells. These results confirm, in human, data previously reported in mice. Moreover, the flow cytometry assay we developed could allow for a more precise enumeration of repopulating primitive progenitors in the course of HSC transplantation.
Keyphrases
- reactive oxygen species
- induced apoptosis
- flow cytometry
- endothelial cells
- cell cycle arrest
- bone marrow
- cell death
- gene expression
- cord blood
- dna damage
- induced pluripotent stem cells
- poor prognosis
- mesenchymal stem cells
- type diabetes
- stem cells
- pluripotent stem cells
- skeletal muscle
- signaling pathway
- deep learning
- insulin resistance
- genetic diversity